A C Hurt

Summary

Affiliation: WHO Collaborating Centre for Reference and Research on Influenza
Country: Australia

Publications

  1. Farrukee R, Zarebski A, McCaw J, Bloom J, Reading P, Hurt A. CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY. Antimicrob Agents Chemother. 2018;: pubmed publisher
    ..Our results highlight the need to carefully monitor circulating viruses for the spread of influenza B viruses with the D197N NA substitution. ..
  2. Panozzo J, Oh D, Margo K, Morton D, Piedrafita D, Mosse J, et al. Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection. Antiviral Res. 2015;120:66-71 pubmed publisher
  3. Hurt A, Ernest J, Deng Y, Iannello P, Besselaar T, Birch C, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009;83:90-3 pubmed publisher
    ..The mutation had no impact on zanamivir susceptibility. Ongoing surveillance is essential to monitor how these strains may spread or persist in the future and to evaluate the effectiveness of treatments against them. ..
  4. Hurt A, Holien J, Parker M, Barr I. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs. 2009;69:2523-31 pubmed publisher
  5. Hurt A, Nor e S, McCaw J, Fryer H, Mosse J, McLean A, et al. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol. 2010;84:9427-38 pubmed publisher
    ..Our statistical inferences are essential for the development of the next generation of mathematical models of the emergence and spread of oseltamivir-resistant influenza in human populations. ..
  6. Hurt A. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8:22-9 pubmed publisher
  7. Meijer A, Rebelo de Andrade H, Correia V, BESSELAAR T, Drager Dayal R, Fry A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Res. 2014;110:31-41 pubmed publisher
    ..Consequently, these drugs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections. ..
  8. Farrukee R, Leang S, Butler J, Lee R, Maurer Stroh S, Tilmanis D, et al. Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility. J Antimicrob Chemother. 2015;70:2004-12 pubmed publisher
  9. Hurt A, Su Y, Aban M, Peck H, Lau H, Baas C, et al. Evidence for the Introduction, Reassortment, and Persistence of Diverse Influenza A Viruses in Antarctica. J Virol. 2016;90:9674-9682 pubmed
    ..The introduction of a highly pathogenic influenza virus in penguin colonies within Antarctica might have devastating consequences. ..

More Information

Publications14

  1. Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo de Andrade H, BESSELAAR T, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res. 2015;117:27-38 pubmed publisher
    ..Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective. ..
  2. Hurt A, Lowther S, Middleton D, Barr I. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Res. 2010;87:361-6 pubmed publisher
    ..Further animal studies and human clinical trials are necessary to optimize neuraminidase inhibitor dosing strategies for the treatment of influenza A(H5N1) infections. ..
  3. Hurt A, Besselaar T, Daniels R, Ermetal B, Fry A, Gubareva L, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015. Antiviral Res. 2016;132:178-85 pubmed publisher
    ..9%), but similar to the 2012-13 period (0.6%). Based on the current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections. ..
  4. Leang S, Hurt A. Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals. J Vis Exp. 2017;: pubmed publisher
    ..Therefore, the inhibitory effect of an NA inhibitor on the influenza virus NA is determined based on the concentration of the NA inhibitor that is required to reduce 50% of the NA activity, given as an IC50 value. ..
  5. Tilmanis D, van Baalen C, Oh D, Rossignol J, Hurt A. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antiviral Res. 2017;147:142-148 pubmed publisher